Follistatin Alleviates Hepatic Steatosis in NAFLD via the mTOR Dependent Pathway.

Junlu TongLi CongYingbin JiaBai-Liang HeYifan GuoJianzhong HeDecheng LiBaojia ZouJian Li

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2022)

Hepatic FST expression increases in NAFLD and plays a protective role in hepatic steatosis. FST overexpression gene therapy alleviates hepatic steatosis via the mTOR pathway.Therefore, gene therapy for FST is a promising treatment in NAFLD.

Keyphrases

combination therapy
gene therapy
cell proliferation
poor prognosis
mouse model
genome wide
transcription factor
gene expression
binding protein
dna methylation
long non coding rna
replacement therapy